Axsome Therapeutics Achieves FDA NDA Acceptance for Migraine Treatment
Axsome Therapeutics, Inc. (NASDAQ: AXSM) has reached an important milestone with the FDA's acceptance of its resubmitted new drug application (NDA) for AXS-07, a novel treatment designed to alleviate acute migraine episodes. This development paves the way for potential approval and has generated renewed interest in the company's stock.
The FDA has established a timeline for a final decision, expected by January 31, 2025, and has classified this NDA resubmission as a Class 2 resubmission, which entails a more thorough review process.
Following this announcement, AXSM shares saw a significant increase of 6.6% on September 4, reflecting positive market sentiment. Year to date, Axsome’s stock price has risen by 20.1%, in contrast to a slight dip in the broader industry, which has seen a decrease of 0.9%.
Overcoming Previous Challenges: The Path to Resubmission
Initially, the FDA issued a complete response letter regarding the first NDA for AXS-07 back in April 2022, highlighting concerns related to its chemistry, manufacturing, and controls. In response, Axsome worked diligently to resolve these issues and completed the NDA resubmission in the second quarter of 2024. Notably, the FDA did not request any additional data on safety or efficacy during this latest review, which further enhances the chances of AXS-07 receiving approval.
Expanding Axsome's Product Portfolio
If AXS-07 is approved, it will add to Axsome's current commercial offerings, which include Auvelity (AXS-05) for major depressive disorder and Sunosi (solriamfetol) for narcolepsy. The approval of AXS-07 would significantly broaden Axsome’s therapeutic range.
Auvelity, launched in 2022, has already shown strong sales performance, generating an impressive $118.4 million in revenue during the first half of 2024, reflecting a remarkable increase of 172.8% compared to the previous year. This growth highlights the strong demand for the medication in the market.
Meanwhile, Sunosi, which Axsome acquired from Jazz Pharmaceuticals (NASDAQ: JAZZ), received FDA approval in 2019 for treating narcolepsy. Since its commercial launch in May 2022, Sunosi’s sales have also shown positive growth, contributing $42.2 million in net product sales during the first half of 2024, marking a year-over-year increase of 35.2%.
Current Stock Status and Market Comparisons
Currently, Axsome holds a Zacks Rank of #3 (Hold), indicating a neutral outlook based on market assessments. However, investors seeking stronger opportunities might consider other biotech stocks with higher rankings.
Companies such as Krystal Biotech, Inc. (NASDAQ: KRYS) and Fulcrum Therapeutics, Inc. (NASDAQ: FULC) currently hold Zacks Rank #1 (Strong Buy), reflecting favorable market conditions and investor confidence. Recent performance shows that Krystal Biotech's earnings estimates for 2024 have risen significantly, jumping from $1.98 to $2.38. Additionally, shares have surged by 50.6% this year.
Similarly, Fulcrum Therapeutics has reduced its projected losses for 2024 and seen its share prices increase by 22.2% year to date, indicating positive growth trends that have attracted investor interest.
Looking Forward: Future Prospects for AXSM
As Axsome Therapeutics moves forward with its potential milestones regarding AXS-07, the company’s future looks promising in the pharmaceutical landscape. With two marketed products already contributing to revenue and the possibility of a third, Axsome is strategically positioning itself for continued growth and innovation in the treatment of neurological disorders.
Frequently Asked Questions
What is AXS-07, and what does it treat?
AXS-07 is a medication developed by Axsome Therapeutics intended for the acute treatment of migraine episodes.
When is the FDA expected to make a decision on AXS-07?
The FDA is expected to provide a final decision regarding AXS-07 by January 31, 2025.
How has AXSM's stock performed recently?
AXSM's stock increased by 6.6% following the FDA's acceptance of the NDA resubmission, and it has rallied 20.1% year to date.
What other products does Axsome Therapeutics have on the market?
Axsome currently markets Auvelity for major depressive disorder and Sunosi for narcolepsy.
What are the other biotech stocks to watch?
Investors may look at Krystal Biotech (KRYS) and Fulcrum Therapeutics (FULC), both currently holding strong rankings and positive growth forecasts.
